BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the colorectal cancer (CRC) drug market in Russia will grow 3 percent annually to $487 million in 2016. According to Colorectal Cancer in Russia, changes in medical practice, a growing CRC patient population and the launches of four novel branded CRC therapies are key factors contributing to this growth.
Anticipated changes in medical practice include increased access to KRAS testing in Russia, which in turn will increase the use of premium-priced EGFR inhibitors such as Merck’s Erbitux and Amgen’s Vectibix as the testing will identify potential responders to these two therapies. Additionally, the introduction of Erbitux onto Russia’s List of Essential Medicines and the anticipated inclusion of Vectibix on the same registry before 2016 will likely lead to an increase in the use of these agents.
“Testing for KRAS mutations was not included in the 2006 Russian CRC treatment guidelines nor is the cost of testing currently covered by mandatory health insurance,” said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. “Nevertheless, Russian oncologists we interviewed are optimistic that testing will become more readily available in the future. Many cite the Improvement of Molecular-Genetic Testing for Oncology Diseases in the Russian Federation that is funded by Merck and AstraZeneca as a key to their anticipated increase in the rates of genetic testing.”
The report also forecasts a launch of four novel branded therapies in Russia between 2013 and 2016, namely, Regeneron/Sanofi’s Zaltrap—which is expected to become the highest-selling new therapy to enter the market during Decision Resources’ forecast period—Bayer’s regorafenib, Alchemia’s HA-irinotecan and ImClone Systems/Eli Lilly’s ramucirumab.
The new report features extensive primary research with Russian oncologists as well as a market outlook by drug and class through 2016 and colorectal cancer epidemiology through 2021.
About Emerging Markets Reports
Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.